MG
UBX

Michael Gelband’s Unity Biotechnology UBX Stock Holding History

Michael Gelband’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-93,597
Closed -$153K – 2259
2023
Q1 		$153K Buy
93,597
+17,697
+23% +$70.9K ﹤0.01% 1601
2022
Q4 		$208K Buy
75,900
+24,911
+49% +$72.4K ﹤0.01% 1450
2022
Q3 		$201K Buy
+50,989
New +$322K ﹤0.01% 1639
2022
Q1 		– Sell
-4,787
Closed -$70K – 2697
2021
Q4 		$70K Buy
4,787
+3,264
+214% +$71.3K ﹤0.01% 2002
2021
Q3 		$46K Sell
1,523
-2,266
-60% -$80K ﹤0.01% 1978
2021
Q2 		$176K Buy
3,789
+1,457
+62% +$70.2K ﹤0.01% 2025
2021
Q1 		$140K Buy
2,332
+295
+14% +$20.1K ﹤0.01% 1934
2020
Q4 		$107K Buy
+2,037
New +$98.2K ﹤0.01% 1826

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Michael Gelband's UBX Position: Q2 2023 in Review

Michael Gelband sold out of Unity Biotechnology (UBX) in Q2 2023, closing a stake of 93,597 shares — an estimated $153K sold.

Michael Gelband first reported a position in UBX in Q4 2020 and held it in 8 quarters. The position peaked at $208K in Q4 2022. 40 funds tracked by Wall St. Rank hold UBX as of Q2 2023.

  • Michael Gelband reported no remaining Unity Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Michael Gelband sold 93,597 Unity Biotechnology shares in Q2 2023, an estimated $153K.
  • Michael Gelband first reported a position in Unity Biotechnology in Q4 2020 and held it in 8 quarters.
  • Michael Gelband's Unity Biotechnology position peaked at $208K in Q4 2022.
  • 40 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.